Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Free Cash Flow (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Free Cash Flow for 6 consecutive years, with -$44.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 22.47% to -$44.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$235.9 million through Dec 2025, up 6.08% year-over-year, with the annual reading at -$235.9 million for FY2025, 6.08% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$44.9 million at Relay Therapeutics, up from -$62.1 million in the prior quarter.
  • The five-year high for Free Cash Flow was $46.5 million in Q1 2021, with the low at -$89.3 million in Q4 2023.
  • Average Free Cash Flow over 5 years is -$55.4 million, with a median of -$59.2 million recorded in 2022.
  • The sharpest move saw Free Cash Flow skyrocketed 299.28% in 2021, then crashed 211.66% in 2022.
  • Over 5 years, Free Cash Flow stood at -$43.1 million in 2021, then tumbled by 37.66% to -$59.4 million in 2022, then plummeted by 50.36% to -$89.3 million in 2023, then surged by 35.2% to -$57.9 million in 2024, then rose by 22.47% to -$44.9 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$44.9 million, -$62.1 million, and -$55.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.